Pharmacogenomics of antidepressant treatment effects

Julio Licinio, Ma-Li Wong

    Research output: Contribution to journalArticlepeer-review

    35 Citations (Scopus)


    There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

    Original languageEnglish
    Pages (from-to)63-71
    Number of pages9
    JournalDialogues in Clinical Neuroscience
    Issue number1
    Publication statusPublished - 2011


    Dive into the research topics of 'Pharmacogenomics of antidepressant treatment effects'. Together they form a unique fingerprint.

    Cite this